Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 955

The DOI matches its Crossref record; 271 of the 271 references it cites were found in a registry or an index.

Hepatitis C Guidance 2019 Update: American Association for the Study of Liver Diseases–Infectious Diseases Society of America Recommendations for Testing, Managing, and Treating Hepatitis C Virus Infection

Open access
Ghany, Marc G., Morgan, Timothy R., AASLD‐IDSA Hepatitis C Guidance Panel·2020·Hepatology

Abstract

The American Association for the Study of Liver Diseases (AASLD) and the Infectious Diseases Society of America (IDSA) initiated the hepatitis C virus (HCV) guidance project (hereafter HCV guidance) in 2013. The AASLD-IDSA HCV guidance website (www.HCVGuidelines.org) disseminates up-to-date, peer-reviewed, unbiased, evidence-based recommendations to aid clinicians making decisions regarding the testing, management, and treatment of HCV infection. Using a web-based system enables timely and nimble distribution of the HCV guidance, which is periodically updated in near real time as necessitated by emerging research data, recommendations from public health agencies, the availability of therapeutic agents, or other significant developments affecting the rapidly evolving hepatitis C arena. The value and utility of the online HCV guidance to the community of hepatitis C care providers throughout the world is evidence by the nearly 10 million pageviews by 1.5 million users originating from 228 countries and territories since the January 2014 launch of the website. A major update of the HCV guidance was released electronically in November 2019. This HCV guidance update summarizes and highlights key new or amended recommendations since the previous October 2018 print publication.1 The advent of safe, well-tolerated, and highly efficacious (>95% cure rate)2 direct-acting antiviral (DAA) therapy for HCV infection has ushered in an era in which elimination of hepatitis C is conceivable. In 2016, the World Health Organization (WHO) proposed a global health sector strategy to eliminate hepatitis C as a public health threat by 2030 and developed an action plan to facilitate this goal.3 In response to the WHO action plan, the National Academies of Science, Engineering, and Medicine (NASEM) developed a US strategy for the elimination of hepatitis C.4 Key elements of the elimination plan include improved detection of undiagnosed cases, increased linkage and access to care for newly diagnosed persons, and expanded treatment access. Many of the recommendations included in the latest update to the HCV guidance and highlighted herein align with and support the goals of the NASEM and WHO strategies to move from control to eventual elimination of hepatitis C. Topics addressed include universal and risk-based hepatitis C screening, simplified treatment algorithms for treatment-naive adults without cirrhosis or with compensated cirrhosis, hepatitis C management in the pediatric population, acute hepatitis C testing and management, and transplantation of organs from HCV-viremic donors into HCV-negative recipients. For detailed evidence reviews related to these topics and information addressing other aspects of HCV testing and management, see the online HCV guidance (www.HCVGuidelines.org). The HCV guidance was developed and is updated by a volunteer panel (representing the AASLD and the IDSA) of hepatology and infectious diseases clinicians with hepatitis C expertise using an evidence-based review of available data, including information presented at scientific conferences and published in peer-reviewed journals. Based on scientific evidence and expert opinion, recommendations are rated by the level of evidence (I, II, or III) and the strength of the recommendation (A, B, or C) using a system adapted from the American College of Cardiology and the American Heart Association.5, 6 See the original AASLD–IDSA hepatitis C guidance publication7 or the HCV guidance website for additional details about the processes and methods employed. All recommendations are reviewed and approved by the governing boards of the AASLD and the IDSA. The HCV guidance panel classifies therapeutic regimens as recommended, alternative, or not recommended based on patient factors (i.e., treatment-naive versus experienced, cirrhosis status, and comorbidities) and viral characteristics (i.e., genotype, subtype, resistance-associated substitutions). Recommended regimens are considered equivalent; alternative regimens are effective but, compared to recommended regimens, have potential disadvantages, limitations for use in certain patient populations, or less supporting data. The identification of risk factors associated with contracting HCV infection served as the basis for the risk-based hepatitis C screening recommendations issued by the US Centers for Disease Control and Prevention (CDC) in 1998.8 Although sensitive for the identification of persons with chronic HCV infection, risk-based screening failed to identify the majority of individuals with HCV infection due to both clinician and patient barriers.9-12 Analysis of the 2003-2010 National Health and Nutrition Examination Survey prevalence data demonstrated that approximately three fourths of individuals with chronic hepatitis C in the United States belonged to the 1945-1965 birth cohort.13 Based on these data, both the CDC and the US Preventive Services Task Force (USPSTF) recommended one-time hepatitis C sc

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1002/hep.31060

Cites

271 of 271 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Items 201–271 of 271

Research works printed but not linked: 125

  1. 2015, Comparison of risk‐based hepatitis C screening and the true seroprevalence in an urban prison system, J Urban Health, 92, 379, 10.1007/s11524-015-9945-4 · doi:10.1007/s11524-015-9945-4
  2. 2018, Healthcare value of implementing hepatitis C screening in the adult general population in Spain, PLoS One, 13
  3. 2016, Evaluation of the Centers for Disease Control and Prevention recommendations for hepatitis C virus testing in an urban emergency department, Clin Infect Dis, 62, 1059, 10.1093/cid/ciw074 · doi:10.1093/cid/ciw074
  4. 2016, Prevalence of diagnosed and undiagnosed hepatitis C in a midwestern urban emergency department, Clin Infect Dis, 62, 1066, 10.1093/cid/ciw073 · doi:10.1093/cid/ciw073
  5. 2015, High hepatitis C virus prevalence and incidence in a community cohort of young heroin injectors in a context of extensive harm reduction programmes, J Epidemiol Community Health, 69, 599, 10.1136/jech-2014-205070 · doi:10.1136/jech-2014-205070
  6. 2012, HCV seroconversion among never‐injecting heroin users at baseline: no predictors identified other than starting injection, Int J Drug Policy, 23, 415, 10.1016/j.drugpo.2012.02.002 · doi:10.1016/j.drugpo.2012.02.002
  7. 2016, Prospective assessment of rapid diagnostic tests for the detection of antibodies to hepatitis C virus, a tool for improving access to care, Clin Microbiol Infect, 22, 459.e1, 10.1016/j.cmi.2016.01.009 · doi:10.1016/j.cmi.2016.01.009
  8. 2016, Identification and clinical management of persons with chronic hepatitis C virus infection—Cherokee Nation, 2012‐2015, MMWR Morb Mortal Wkly Rep, 65, 461, 10.15585/mmwr.mm6518a2 · doi:10.15585/mmwr.mm6518a2
  9. 2008, Validation of a strategy for HCV antibody testing with two enzyme immunoassays in a routine clinical laboratory, J Clin Virol, 42, 394, 10.1016/j.jcv.2008.02.015 · doi:10.1016/j.jcv.2008.02.015
  10. 1996, Progression of type C chronic hepatitis to liver cirrhosis and hepatocellular carcinoma—its relationship to alcohol drinking and the age of transfusion, Alcohol Clin Exp Res, 20, 95A
  11. 2019, Liver stiffness assessed by ultrasound shear wave elastography from General Electric accurately predicts clinically significant portal hypertension in patients with advanced chronic liver disease, Ultraschall Med
  12. 2017, The negative impact of HBV/HCV coinfection on cirrhosis and its consequences, Aliment Pharmacol Ther, 46, 1054, 10.1111/apt.14352 · doi:10.1111/apt.14352
  13. 2019, Trends in treatment uptake and provider specialty for hepatitis C virus (HCV) infection in the Veterans Affairs healthcare system: results from the Electronically Retrieved Cohort of HCV‐Infected Veterans (ERCHIVES), Clin Infect Dis, 68, 857, 10.1093/cid/ciy697 · doi:10.1093/cid/ciy697
  14. 2017, Barriers to hepatitis C treatment in the era of direct‐acting anti‐viral agents, Aliment Pharmacol Ther, 46, 992, 10.1111/apt.14328 · doi:10.1111/apt.14328
  15. 2018, Differential effect of HCV eradication and fibrosis grade on hepatocellular carcinoma and all‐cause mortality, Sci Rep, 8, 12146
  16. 2018, Impact of sustained virologic response on short‐term clinical outcomes in hepatitis C–related cirrhosis, Eur J Gastroenterol Hepatol, 30, 296, 10.1097/MEG.0000000000001032 · doi:10.1097/meg.0000000000001032
  17. 2017, Hepatocellular carcinoma decreases the chance of successful hepatitis C virus therapy with direct‐acting antivirals, J Hepatol, 66, 1173, 10.1016/j.jhep.2017.01.020 · doi:10.1016/j.jhep.2017.01.020
  18. 2019, Clinical practice: hepatitis C virus infection, cryoglobulinemia and cryoglobulinemic vasculitis, Clin Exp Med, 19, 1, 10.1007/s10238-018-0536-z · doi:10.1007/s10238-018-0536-z
  19. 2017, Direct‐acting antiviral agents in the therapy of hepatitis C virus–related mixed cryoglobulinaemia: a single‐centre experience, Arthritis Res Ther, 19, 74, 10.1186/s13075-017-1280-6 · doi:10.1186/s13075-017-1280-6
  20. 2019, Rapid regression of B‐cell non‐Hodgkin's lymphoma after eradication of hepatitis C virus by direct antiviral agents, Case Rep Gastroenterol, 13, 336, 10.1159/000501546 · doi:10.1159/000501546
  21. 2019, miRNA‐26b downregulation in peripheral blood mononuclear cells of patients with hepatitis C associated lymphomas is restored by successful interferon‐free antiviral therapy, Antivir Ther
  22. 2019, Lymphomas associated with chronic hepatitis C virus infection: a prospective multicenter cohort study from the Rete Ematologica Lombarda (REL) clinical network, Hematol Oncol, 37, 160, 10.1002/hon.2575 · doi:10.1002/hon.2575
  23. 2012, Regression of Hodgkin lymphoma in response to antiviral therapy for hepatitis C virus infection, Intern Med, 51, 2745, 10.2169/internalmedicine.51.8404 · doi:10.2169/internalmedicine.51.8404
  24. 2005, Systematic review: regression of lymphoproliferative disorders after treatment for hepatitis C infection, Aliment Pharmacol Ther, 21, 653, 10.1111/j.1365-2036.2005.02395.x · doi:10.1111/j.1365-2036.2005.02395.x
  25. 2005, Regression of advanced non‐splenic marginal zone lymphoma after treatment of hepatitis C virus infection, Leuk Lymphoma, 46, 1365, 10.1080/104281905001028289 · doi:10.1080/104281905001028289
  26. 2002, Regression of splenic lymphoma after treatment of hepatitis C virus infection, N Engl J Med, 347, 2168, 10.1056/NEJM200212263472614 · doi:10.1056/nejm200212263472614
  27. 2006, Improvement in quality of life measures in patients with refractory hepatitis C, responding to re‐treatment with pegylated interferon alpha ‐2b and ribavirin, Health Qual Life Outcomes, 4, 30, 10.1186/1477-7525-4-30 · doi:10.1186/1477-7525-4-30
  28. 2019, A systematic review and meta‐analysis of community and primary‐care‐based hepatitis C testing and treatment services that employ direct acting antiviral drug treatments, BMC Health Serv Res, 19, 765, 10.1186/s12913-019-4635-7 · doi:10.1186/s12913-019-4635-7
  29. 2018, Direct‐acting antiviral therapy for hepatitis C infection among people receiving opioid agonist treatment or heroin assisted treatment, Int J Drug Policy, 62, 74, 10.1016/j.drugpo.2018.10.003 · doi:10.1016/j.drugpo.2018.10.003
  30. 2017, Expansion of treatment for hepatitis C virus infection by task shifting to community‐based nonspecialist providers: a nonrandomized clinical trial, Ann Intern Med, 167, 311, 10.7326/M17-0118 · doi:10.7326/m17-0118
  31. 2018, Glucose metabolism changes in patients with chronic hepatitis C treated with direct acting antivirals, Can J Gastroenterol Hepatol, 2018, 6095097
  32. 2016, Rapid decline of fasting glucose in HCV diabetic patients treated with direct‐acting antiviral agents, Clin Microbiol Infect, 22, 462.e1, 10.1016/j.cmi.2015.12.030 · doi:10.1016/j.cmi.2015.12.030
  33. 2016, Hypoglycemia in a diabetic patient during hepatitis C therapy, Hepatology, 63, 2065, 10.1002/hep.28137 · doi:10.1002/hep.28137
  34. 2017, Reduction in warfarin effect associated with sofosbuvir–velpatasvir, Am J Health Syst Pharm, 74, 1308, 10.2146/ajhp170324 · doi:10.2146/ajhp170324
  35. 2019, Safety and efficacy of glecaprevir/pibrentasvir for the treatment of chronic hepatitis C in patients aged 65 years or older, PLoS One, 14
  36. 2019, Integrated analysis of 8‐week glecaprevir/pibrentasvir in Japanese and overseas patients without cirrhosis and with hepatitis C virus genotype 1 or 2 infection, J Gastroenterol, 54, 752, 10.1007/s00535-019-01569-7 · doi:10.1007/s00535-019-01569-7
  37. 2019, Safety and efficacy of glecaprevir/pibrentasvir for the treatment of HCV genotype 1‐6: results of the HCV‐Target Study [Abstract 956], Gastroenterology, 156, S1220
  38. 2018, Efficacy and safety of glecaprevir/pibrentasvir in Japanese patients with chronic genotype 1 hepatitis C virus infection with and without cirrhosis, J Gastroenterol, 53, 557, 10.1007/s00535-017-1391-5 · doi:10.1007/s00535-017-1391-5
  39. 2018, High SVR12 with 8‐week and 12‐week glecaprevir/pibrentasvir therapy: an integrated analysis of HCV genotype 1‐6 patients without cirrhosis, J Hepatol, 69, 293, 10.1016/j.jhep.2018.03.007 · doi:10.1016/j.jhep.2018.03.007
  40. 2019, Sofosbuvir/velpatasvir for the treatment of HCV: excellent results from a phase‐3, open‐label study in Russia and Sweden, Infect Dis (Lond), 51, 131, 10.1080/23744235.2018.1535186 · doi:10.1080/23744235.2018.1535186
  41. 2019, Sofosbuvir–velpatasvir for treatment of chronic hepatitis C virus infection in Asia: a single‐arm, open‐label, phase 3 trial, Lancet Gastroenterol Hepatol, 4, 127, 10.1016/S2468-1253(18)30343-1 · doi:10.1016/s2468-1253(18)30343-1
  42. 2018, Resistance analysis in patients with genotype 1‐6 HCV infection treated with sofosbuvir/velpatasvir in the phase III studies, J Hepatol, 68, 895, 10.1016/j.jhep.2017.11.032 · doi:10.1016/j.jhep.2017.11.032
  43. 2019, Real‐world effectiveness and safety of glecaprevir/pibrentasvir for the treatment of chronic hepatitis C infection: data from the German Hepatitis C‐Registry, Aliment Pharmacol Ther, 49, 1052, 10.1111/apt.15222 · doi:10.1111/apt.15222
  44. 2019, Effectiveness of therapy in 16,567 directly‐acting antiviral treated people in England: high response rates in genotype 3 hepatitis C infection regardless of degree of fibrosis, but ribavirin improves response in cirrhosis, J Hepatol, 70, e131, 10.1016/S0618-8278(19)30231-2 · doi:10.1016/s0618-8278(19)30231-2
  45. 2019, Sustained virologic response rates in patients with chronic hepatitis C genotype 6 treated with ledipasvir+sofosbuvir or sofosbuvir+velpatasvir, Aliment Pharmacol Ther, 49, 99, 10.1111/apt.15043 · doi:10.1111/apt.15043
  46. 2019, Safety and efficacy of sofosbuvir‐based direct‐acting antiviral regimens for hepatitis C virus genotype 6 in southwest China: real‐world experience of a retrospective study, J Viral Hepat, 26, 316, 10.1111/jvh.13033 · doi:10.1111/jvh.13033
  47. 2018, High efficacy of sofosbuvir/velpatasvir and impact of baseline resistance‐associated substitutions in hepatitis C genotype 3 infection, Aliment Pharmacol Ther, 47, 1288, 10.1111/apt.14592 · doi:10.1111/apt.14592
  48. 2017, Late relapse versus hepatitis C virus reinfection in patients with sustained virologic response after sofosbuvir‐based therapies, Clin Infect Dis, 64, 44, 10.1093/cid/ciw676 · doi:10.1093/cid/ciw676
  49. 2019, Glecaprevir/pibrentasvir for 8 weeks in treatment‐naive patients with chronic HCV genotypes 1‐6 and compensated cirrhosis: the EXPEDITION‐8 trial, J Hepatol
  50. 2016, 100% SVR4 with ABT‐493 and ABT‐530 with or without ribavirin in treatment‐naive HCV genotype 3‐infected patients with cirrhosis, J Hepatol, 64, S208, 10.1016/S0168-8278(16)00170-7 · doi:10.1016/s0168-8278(16)00170-7
  51. 2018, Efficacy of sofosbuvir and velpatasvir, with and without ribavirin, in patients with hepatitis C virus genotype 3 infection and cirrhosis, Gastroenterology, 155, 1120, 10.1053/j.gastro.2018.06.042 · doi:10.1053/j.gastro.2018.06.042
  52. 2018, Sofosbuvir/velpatasvir in patients with hepatitis C virus genotypes 1‐6 and compensated cirrhosis or advanced fibrosis, Liver Int, 38, 443, 10.1111/liv.13534 · doi:10.1111/liv.13534
  53. 2019, Real‐life glecaprevir/pibrentasvir in a large cohort of patients with hepatitis C virus infection: the MISTRAL study, Liver Int, 39, 1852, 10.1111/liv.14170 · doi:10.1111/liv.14170
  54. 2019, Glecaprevir and pibrentasvir for Japanese patients with chronic hepatitis C genotype 1 or 2 infection: results from a multicenter, real‐world cohort study, Hepatol Res, 49, 617, 10.1111/hepr.13328 · doi:10.1111/hepr.13328
  55. 2019, Real‐world experience of 12‐week DAA regimen of glecaprevir and pibrentasvir in patients with chronic HCV infection, J Gastroenterol Hepatol
  56. 2019, Real‐world effectiveness of daclatasvir plus sofosbuvir and velpatasvir/sofosbuvir in hepatitis C genotype 2 and 3, J Hepatol, 70, 15, 10.1016/j.jhep.2018.09.018 · doi:10.1016/j.jhep.2018.09.018
  57. 2019, A retrospective study of the efficacy of sofosbuvir plus NS5A inhibitors for patients with hepatitis C virus genotype‐2 chronic infection, Eur J Gastroenterol Hepatol, 31, 382, 10.1097/MEG.0000000000001299 · doi:10.1097/meg.0000000000001299
  58. 2018, Sofosbuvir based regimens in the treatment of chronic hepatitis C genotype 1 infection in African‐American patients: a community‐based retrospective cohort study, Eur J Gastroenterol Hepatol, 30, 1200, 10.1097/MEG.0000000000001233 · doi:10.1097/meg.0000000000001233
  59. 2018, Satisfactory virological response and fibrosis improvement of sofosbuvir‐based regimens for Chinese patients with hepatitis C virus genotype 3 infection: results of a real‐world cohort study, Virol J, 15, 150, 10.1186/s12985-018-1066-8 · doi:10.1186/s12985-018-1066-8
  60. 2006, The burden of hepatitis C virus infection in children: estimated direct medical costs over a 10‐year period, J Pediatr, 148, 353, 10.1016/j.jpeds.2005.10.031 · doi:10.1016/j.jpeds.2005.10.031
  61. 2015, Hepatitis C virus (HCV) vertical transmission in 12‐month‐old infants born to HCV‐infected women and assessment of maternal risk factors, Open Forum Infect Dis, 2, ofv089, 10.1093/ofid/ofv089 · doi:10.1093/ofid/ofv089
  62. 2001, Vertical transmission of hepatitis C virus in a cohort of 2,447 HIV‐seronegative pregnant women: a 24‐month prospective study, J Pediatr Gastroenterol Nutr, 33, 570
  63. 2012, Anti‐HCV testing as a basic standard of monitoring HCV mother‐to‐child infection: advantages and disadvantages of the method, Przegl Epidemiol, 66, 341
  64. 2005, Excluding hepatitis C virus (HCV) infection by serology in young infants of HCV‐infected mothers, Acta Paediatr, 94, 444, 10.1111/j.1651-2227.2005.tb01916.x · doi:10.1111/j.1651-2227.2005.tb01916.x
  65. 2012, Spontaneous clearance of hepatitis C virus in vertically infected children, Eur J Pediatr, 171, 253, 10.1007/s00431-011-1517-3 · doi:10.1007/s00431-011-1517-3
  66. 2016, Hepatitis C viraemia after apparent spontaneous clearance in a vertically infected child, Lancet, 387, 1967, 10.1016/S0140-6736(16)00085-4 · doi:10.1016/s0140-6736(16)00085-4
  67. 2018, Polymerase chain reaction (PCR) for detection of vertically acquired hepatitis C virus (HCV) infection in early infancy, Open Forum Infect Dis, 5, S654
  68. 2009, Impact of hepatitis C virus infection on children and their caregivers: quality of life, cognitive, and emotional outcomes, J Pediatr Gastroenterol Nutr, 48, 341, 10.1097/MPG.0b013e318185998f · doi:10.1097/mpg.0b013e318185998f
  69. 2008, Health‐related quality of life in children with hepatitis C acquired in the first year of life, J Gastroenterol Hepatol, 23, 226, 10.1111/j.1440-1746.2007.04859.x · doi:10.1111/j.1440-1746.2007.04859.x
  70. 2017, Clinical usefulness of new noninvasive serum biomarkers for the assessment of liver fibrosis and steatosis in children with chronic hepatitis C, Clin Exp Hepatol, 3, 198
  71. 2016, Transient liver elastography in unsedated control children: impact of age and intercurrent illness, J Paediatr Child Health, 52, 637, 10.1111/jpc.13151 · doi:10.1111/jpc.13151
  72. 2013, Serum biomarkers and transient elastography as predictors of advanced liver fibrosis in a United States cohort: the Boston Children's Hospital experience, J Pediatr, 163, 1058, 10.1016/j.jpeds.2013.04.044 · doi:10.1016/j.jpeds.2013.04.044
  73. 2018, Epidemiologic features of 348 children with hepatitis C virus infection over a 30‐year period: a nationwide survey in Japan, J Gastroenterol, 53, 419, 10.1007/s00535-017-1351-0 · doi:10.1007/s00535-017-1351-0
  74. 2008, Long‐term course of chronic hepatitis C in children: from viral clearance to end‐stage liver disease, Gastroenterology, 134, 1900, 10.1053/j.gastro.2008.02.082 · doi:10.1053/j.gastro.2008.02.082
  75. 2010, Influence of body mass index on outcome of pediatric chronic hepatitis C virus infection, J Pediatr Gastroenterol Nutr, 51, 191, 10.1097/MPG.0b013e3181d32756 · doi:10.1097/mpg.0b013e3181d32756
  76. 2011, Diagnosis and management of hepatitis C virus–infected children, Pediatr Infect Dis J, 30, 983, 10.1097/INF.0b013e318236ac37 · doi:10.1097/inf.0b013e318236ac37
  77. 2008, Pathology of chronic hepatitis C in children: liver biopsy findings in the Peds‐C Trial, Hepatology, 47, 836, 10.1002/hep.22094 · doi:10.1002/hep.22094
  78. 2006, Hepatitis C in children: a quaternary referral center perspective, J Pediatr Gastroenterol Nutr, 43, 209, 10.1097/01.mpg.0000228117.52229.32 · doi:10.1097/01.mpg.0000228117.52229.32
  79. 2015, Histopathology of hepatitis C in children, a systematic review: implications for treatment, Expert Rev Anti Infect Ther, 13, 1225, 10.1586/14787210.2015.1070668 · doi:10.1586/14787210.2015.1070668
  80. 2013, Evaluating progression of liver disease from repeat liver biopsies in children with chronic hepatitis C: a retrospective study, Hepatology, 58, 1580, 10.1002/hep.26519 · doi:10.1002/hep.26519
  81. 2004, The epidemiology of chronic hepatitis C infection in survivors of childhood cancer: an update of the St Jude Children's Research Hospital hepatitis C seropositive cohort, Blood, 103, 2460, 10.1182/blood-2003-07-2565 · doi:10.1182/blood-2003-07-2565
  82. 1998, Histopathology of the liver in children with chronic hepatitis C viral infection, Hepatology, 28, 1416, 10.1002/hep.510280534 · doi:10.1002/hep.510280534
  83. 1998, Chronic hepatitis C in children: the pathological and clinical spectrum, Gastroenterology, 115, 1525, 10.1016/S0016-5085(98)70032-0 · doi:10.1016/s0016-5085(98)70032-0
  84. 2019, Pharmacokinetics, safety, and efficacy of glecaprevir/pibrentasvir in adolescents with chronic hepatitis C virus: part 1 of the DORA study, Hepatology
  85. 2017, Effectiveness of elbasvir and grazoprevir combination, with or without ribavirin, for treatment‐experienced patients with chronic hepatitis C infection, Gastroenterology, 152, 164, 10.1053/j.gastro.2016.09.045 · doi:10.1053/j.gastro.2016.09.045
  86. 2018, Efficacy of elbasvir and grazoprevir in participants with hepatitis C virus genotype 4 infection: a pooled analysis, Liver Int, 38, 1583, 10.1111/liv.13727 · doi:10.1111/liv.13727
  87. 2018, Glecaprevir/pibrentasvir for hepatitis C virus genotype 3 patients with cirrhosis and/or prior treatment experience: a partially randomized phase 3 clinical trial, Hepatology, 67, 514, 10.1002/hep.29541 · doi:10.1002/hep.29541
  88. 2019, Generic sofosbuvir/ledipasvir for the treatment of genotype 4 chronic hepatitis C in Egyptian children (9‐12 years) and adolescents, Hepatol Int, 13, 706, 10.1007/s12072-019-09985-w · doi:10.1007/s12072-019-09985-w
  89. 2018, Sustained viral response in genotype 4 chronic hepatitis C virus–infected children and adolescents treated with sofosbuvir/ledipasvir, J Pediatr Gastroenterol Nutr, 67, 626, 10.1097/MPG.0000000000002101 · doi:10.1097/mpg.0000000000002101
  90. 2011, The natural history of acute hepatitis C: clinical presentation, laboratory findings and treatment outcomes, Aliment Pharmacol Ther, 33, 559, 10.1111/j.1365-2036.2010.04549.x · doi:10.1111/j.1365-2036.2010.04549.x
  91. 2017, Liver transplantation for fulminant genotype 2a/c hepatitis C virus marked by a rapid recurrence followed by cure, Transpl Infect Dis, 19
  92. 2015, Patterns of hepatitis C virus RNA levels during acute infection: the InC3 study, PLoS One, 10
  93. 2014, Dynamics of HCV RNA levels during acute hepatitis C virus infection, J Med Virol, 86, 1722, 10.1002/jmv.24010 · doi:10.1002/jmv.24010
  94. 2018, Should we treat acute hepatitis C? A decision and cost‐effectiveness analysis, Hepatology, 67, 837, 10.1002/hep.29611 · doi:10.1002/hep.29611
  95. 2012, Infectivity in chimpanzees (Pan troglodytes) of plasma collected before HCV RNA detectability by FDA‐licensed assays: implications for transfusion safety and HCV infection outcomes, Blood, 119, 6326, 10.1182/blood-2011-12-393637 · doi:10.1182/blood-2011-12-393637
  96. 2015, Delta hepatitis within the Veterans Affairs medical system in the United States: prevalence, risk factors, and outcomes, J Hepatol, 63, 586, 10.1016/j.jhep.2015.04.025 · doi:10.1016/j.jhep.2015.04.025
  97. 2008, The course of hepatitis C viraemia in transfusion recipients prior to availability of antiviral therapy, J Viral Hepat, 15, 120, 10.1111/j.1365-2893.2007.00900.x · doi:10.1111/j.1365-2893.2007.00900.x
  98. 2019, Ledipasvir/sofosbuvir for 8 weeks to treat acute hepatitis C virus infections in men with human immunodeficiency virus infections: sofosbuvir‐containing regimens without iInterferon for treatment of acute HCV in HIV‐1 infected individuals, Clin Infect Dis
  99. 2019, Increasing utilization and excellent initial outcomes following liver transplant of hepatitis C virus (HCV)–viremic donors into HCV‐negative recipients: outcomes following liver transplant of HCV‐viremic donors, Hepatology, 69, 2381, 10.1002/hep.30540 · doi:10.1002/hep.30540
  100. 2016, Improving organ utilization to help overcome the tragedies of the opioid epidemic, Am J Transplant, 16, 2836, 10.1111/ajt.13971 · doi:10.1111/ajt.13971
  101. 2019, National trends in utilization and 1‐year outcomes with transplantation of HCV‐viremic kidneys, J Am Soc Nephrol, 30, 1939, 10.1681/ASN.2019050462 · doi:10.1681/asn.2019050462
  102. 2018, Changes in utilization and discard of HCV antibody–positive deceased donor kidneys in the era of direct‐acting antiviral therapy, Transplantation, 102, 2088, 10.1097/TP.0000000000002323 · doi:10.1097/tp.0000000000002323
  103. 2015, Shorter waitlist times and improved graft survivals are observed in patients who accept hepatitis C virus+ renal allografts, Transplantation, 99, 1192, 10.1097/TP.0000000000000479 · doi:10.1097/tp.0000000000000479
  104. 2018, Kidney transplantation and waitlist mortality rates among candidates registered as willing to accept a hepatitis C infected kidney, Transpl Infect Dis, 20
  105. 2018, Hepatitis C transmission from seropositive, nonviremic donors to non‐hepatitis C liver transplant recipients, Hepatology, 67, 1673, 10.1002/hep.29704 · doi:10.1002/hep.29704
  106. 2019, Possible acute rejection associated with the use of the new anti–hepatitis C virus medications, Avicenna J Med, 9, 32, 10.4103/AJM.AJM_171_17 · doi:10.4103/ajm.ajm_171_17
  107. 2018, The impact of direct antiviral therapy for hepatitis C (DAA) on acute rejection and donor specific antibody formation in kidney transplant recipients, evidence from surveillance biopsies, Transplantation, 102, S325
  108. 2017, Efficacy and tolerability of interferon‐free antiviral therapy in kidney transplant recipients with chronic hepatitis C, J Hepatol, 66, 718, 10.1016/j.jhep.2016.12.020 · doi:10.1016/j.jhep.2016.12.020
  109. 2019, Impact of sofosbuvir‐based regimens for the treatment of hepatitis C after liver transplant on renal function: results of a Canadian national retrospective study, Exp Clin Transplant, 17, 59, 10.6002/ect.2017.0201 · doi:10.6002/ect.2017.0201
  110. 2018, Impact of anti‐HCV direct antiviral agents on graft function and immunosuppressive drug levels in kidney transplant recipients: a call to attention in the mid‐term follow‐up in a single‐center cohort study, Transpl Int, 31, 887, 10.1111/tri.13118 · doi:10.1111/tri.13118
  111. 2017, Direct‐acting antiviral agent‐based regimen for HCV recurrence after combined liver–kidney transplantation: results from the ANRS CO23 CUPILT study, Am J Transplant, 17, 2869, 10.1111/ajt.14490 · doi:10.1111/ajt.14490
  112. 2017, Safety and efficacy of treatment of hepatitis C in kidney transplant recipients with directly acting antiviral agents, Transplantation, 101, 1704, 10.1097/TP.0000000000001618 · doi:10.1097/tp.0000000000001618
  113. 2019, Pre‐emptive pangenotypic direct acting antiviral therapy in donor HCV‐positive to recipient HCV‐negative heart transplantation: an open‐label study, Lancet Gastroenterol Hepatol, 4, 771, 10.1016/S2468-1253(19)30240-7 · doi:10.1016/s2468-1253(19)30240-7
  114. 2019, Fibrosing cholestatic hepatitis after kidney transplantation from HCV‐viremic donors to HCV‐negative recipients: a unique complication in the DAA era, Am J Transplant
  115. 2017, Favorable short‐term outcome of hepatitis C virus–positive liver graft with bridging fibrosis: a plea for very early viral eradication, Hepatology, 65, 2116, 10.1002/hep.28978 · doi:10.1002/hep.28978
  116. 2017, Transplanting HCV‐infected kidneys into uninfected recipients, N Engl J Med, 377, 1105
  117. 2017, Effect of hepatic impairment on the pharmacokinetics of grazoprevir, a hepatitis C virus protease inhibitor, Antimicrob Agents Chemother, 61
  118. 2018, The influence of immunosuppressants on direct‐acting antiviral therapy is dependent on the hepatitis C virus genotype, Transpl Infect Dis, 20
  119. 2017, Drug–drug interactions in hepatitis C virus treatment: do they really matter?, Clin Liver Dis (Hoboken), 10, 111, 10.1002/cld.668 · doi:10.1002/cld.668
  120. 2017, Decreased tacrolimus plasma concentrations during HCV therapy: a drug–drug interaction or is there an alternative explanation?, Int J Antimicrob Agents, 49, 379, 10.1016/j.ijantimicag.2016.12.004 · doi:10.1016/j.ijantimicag.2016.12.004
  121. 2016, Pharmacokinetics of tacrolimus and cyclosporine in liver transplant recipients receiving 3 direct‐acting antivirals as treatment for hepatitis C infection, Ther Drug Monit, 38, 640, 10.1097/FTD.0000000000000315 · doi:10.1097/ftd.0000000000000315
  122. 2015, Drug interactions with direct‐acting antivirals for hepatitis C: implications for HIV and transplant patients, Ann Pharmacother, 49, 674, 10.1177/1060028015576180 · doi:10.1177/1060028015576180
  123. 2019, HCV NAT positive solid organ allografts transplanted into HCV negative recipients: a real‐world experience, Hepatology
  124. 2019, Utilization rates and clinical outcomes of hepatitis C positive donor hearts in the contemporary era, J Heart Lung Transplant, 38, 907, 10.1016/j.healun.2019.06.023 · doi:10.1016/j.healun.2019.06.023
  125. 2012, Early viral load and recipient interleukin‐28B rs12979860 genotype are predictors of the progression of hepatitis C after liver transplantation, Liver Transpl, 18, 671, 10.1002/lt.23402 · doi:10.1002/lt.23402

Cited by

See all 955

Metadata

Authors
Ghany, M. G., Morgan, T. R., & Panel, A. H. C. G.
Venue
Hepatology
Published
2020-02
Volume
71
Issue
2
Pages
686-721
ISSN
  • 0270-9139 (ISSN-L)
  • 1527-3350
OpenAlex
W2992772421
Cited by
955
References
271
FWCI
66.55
Type
journal article
Language
en
Open access
green
Licence

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.